Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)

Autores
Waxman Dova, Samanta; Prados, Ana Paula; De Lucas, Julio; Andres, Manuel Ignacio San; Sassaroli, Juan Carlos; Orozco, Maria Marcela; Argibay, Hernán Darío; Rodriguez, Casilda
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
To determine the dosage of enrofloxacin in southern crested caracaras (Caracara plancus), plasma concentrations of enrofloxacin were measured by high-performance liquid chromatography after intravenous (IV) (5 mg/kg) and intramuscular (IM) (10 mg/kg) administration. This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg·h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration. The areas under the concentration-time curves (AUC) were 21.92 and 34.38 μg·h/mL for IM and IV administration, respectively. Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%. After IM administration, the peak drug concentration (Cmax) was 3.92 μg/mL. Values of minimum inhibitory concentration (MIC), Cmax, and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a Cmax/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects. By using the study data and a MIC breakpoint of 0.25 μg/mL, values of Cmax/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively. For the treatment of infectious diseases caused by microorganisms with MIC ≤0.25 μg/mL, the calculated optimal dosages were 7.5 and 9.5 mg/kg q24h by the IV and IM routes, respectively. For less susceptible bacteria, a dose increase should be evaluated. To treat caracara by the IV route against microorganisms with MIC ≤0.25 μg/mL, the dose should be higher than the 5 mg/kg used in our study, but possible side effects derived from an increase in the IV dose and efficacy in sick birds should be assessed.
Fil: Waxman Dova, Samanta. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Prados, Ana Paula. Universidad de Buenos Aires; Argentina
Fil: De Lucas, Julio. Universidad Complutense de Madrid; España
Fil: Andres, Manuel Ignacio San. Universidad Complutense de Madrid; España
Fil: Sassaroli, Juan Carlos. No especifica;
Fil: Orozco, Maria Marcela. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Argibay, Hernán Darío. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rodriguez, Casilda. Universidad Complutense de Madrid; España
Materia
CARACARA PLANCUS
ENROFLOXACIN
FLUOROQUINOLONES PHARMACOKINETICS
PHARMACODYNAMICS
SOUTHERN CREASTED CARACARS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/86056
Acceder
id CONICETDig_4bfad2239061b90597b955666e40ac08
oai_identifier_str oai:ri.conicet.gov.ar:11336/86056
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)Waxman Dova, SamantaPrados, Ana PaulaDe Lucas, JulioAndres, Manuel Ignacio SanSassaroli, Juan CarlosOrozco, Maria MarcelaArgibay, Hernán DaríoRodriguez, CasildaCARACARA PLANCUSENROFLOXACINFLUOROQUINOLONES PHARMACOKINETICSPHARMACODYNAMICSSOUTHERN CREASTED CARACARShttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4To determine the dosage of enrofloxacin in southern crested caracaras (Caracara plancus), plasma concentrations of enrofloxacin were measured by high-performance liquid chromatography after intravenous (IV) (5 mg/kg) and intramuscular (IM) (10 mg/kg) administration. This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg·h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration. The areas under the concentration-time curves (AUC) were 21.92 and 34.38 μg·h/mL for IM and IV administration, respectively. Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%. After IM administration, the peak drug concentration (Cmax) was 3.92 μg/mL. Values of minimum inhibitory concentration (MIC), Cmax, and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a Cmax/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects. By using the study data and a MIC breakpoint of 0.25 μg/mL, values of Cmax/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively. For the treatment of infectious diseases caused by microorganisms with MIC ≤0.25 μg/mL, the calculated optimal dosages were 7.5 and 9.5 mg/kg q24h by the IV and IM routes, respectively. For less susceptible bacteria, a dose increase should be evaluated. To treat caracara by the IV route against microorganisms with MIC ≤0.25 μg/mL, the dose should be higher than the 5 mg/kg used in our study, but possible side effects derived from an increase in the IV dose and efficacy in sick birds should be assessed.Fil: Waxman Dova, Samanta. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Prados, Ana Paula. Universidad de Buenos Aires; ArgentinaFil: De Lucas, Julio. Universidad Complutense de Madrid; EspañaFil: Andres, Manuel Ignacio San. Universidad Complutense de Madrid; EspañaFil: Sassaroli, Juan Carlos. No especifica;Fil: Orozco, Maria Marcela. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Argibay, Hernán Darío. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Rodriguez, Casilda. Universidad Complutense de Madrid; EspañaAssoc Avian Veterinarians2013-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/86056Waxman Dova, Samanta; Prados, Ana Paula; De Lucas, Julio; Andres, Manuel Ignacio San; Sassaroli, Juan Carlos; et al.; Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus); Assoc Avian Veterinarians; Journal Of Avian Medicine And Surgery; 27; 3; 9-2013; 180-1861082-6742CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.bioone.org/doi/full/10.1647/2012-022info:eu-repo/semantics/altIdentifier/doi/10.1647/2012-022info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:05:09Zoai:ri.conicet.gov.ar:11336/86056instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:05:10.253CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
title Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
spellingShingle Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
Waxman Dova, Samanta
CARACARA PLANCUS
ENROFLOXACIN
FLUOROQUINOLONES PHARMACOKINETICS
PHARMACODYNAMICS
SOUTHERN CREASTED CARACARS
title_short Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
title_full Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
title_fullStr Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
title_full_unstemmed Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
title_sort Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus)
dc.creator.none.fl_str_mv Waxman Dova, Samanta
Prados, Ana Paula
De Lucas, Julio
Andres, Manuel Ignacio San
Sassaroli, Juan Carlos
Orozco, Maria Marcela
Argibay, Hernán Darío
Rodriguez, Casilda
author Waxman Dova, Samanta
author_facet Waxman Dova, Samanta
Prados, Ana Paula
De Lucas, Julio
Andres, Manuel Ignacio San
Sassaroli, Juan Carlos
Orozco, Maria Marcela
Argibay, Hernán Darío
Rodriguez, Casilda
author_role author
author2 Prados, Ana Paula
De Lucas, Julio
Andres, Manuel Ignacio San
Sassaroli, Juan Carlos
Orozco, Maria Marcela
Argibay, Hernán Darío
Rodriguez, Casilda
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CARACARA PLANCUS
ENROFLOXACIN
FLUOROQUINOLONES PHARMACOKINETICS
PHARMACODYNAMICS
SOUTHERN CREASTED CARACARS
topic CARACARA PLANCUS
ENROFLOXACIN
FLUOROQUINOLONES PHARMACOKINETICS
PHARMACODYNAMICS
SOUTHERN CREASTED CARACARS
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv To determine the dosage of enrofloxacin in southern crested caracaras (Caracara plancus), plasma concentrations of enrofloxacin were measured by high-performance liquid chromatography after intravenous (IV) (5 mg/kg) and intramuscular (IM) (10 mg/kg) administration. This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg·h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration. The areas under the concentration-time curves (AUC) were 21.92 and 34.38 μg·h/mL for IM and IV administration, respectively. Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%. After IM administration, the peak drug concentration (Cmax) was 3.92 μg/mL. Values of minimum inhibitory concentration (MIC), Cmax, and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a Cmax/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects. By using the study data and a MIC breakpoint of 0.25 μg/mL, values of Cmax/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively. For the treatment of infectious diseases caused by microorganisms with MIC ≤0.25 μg/mL, the calculated optimal dosages were 7.5 and 9.5 mg/kg q24h by the IV and IM routes, respectively. For less susceptible bacteria, a dose increase should be evaluated. To treat caracara by the IV route against microorganisms with MIC ≤0.25 μg/mL, the dose should be higher than the 5 mg/kg used in our study, but possible side effects derived from an increase in the IV dose and efficacy in sick birds should be assessed.
Fil: Waxman Dova, Samanta. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Prados, Ana Paula. Universidad de Buenos Aires; Argentina
Fil: De Lucas, Julio. Universidad Complutense de Madrid; España
Fil: Andres, Manuel Ignacio San. Universidad Complutense de Madrid; España
Fil: Sassaroli, Juan Carlos. No especifica;
Fil: Orozco, Maria Marcela. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Argibay, Hernán Darío. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Rodriguez, Casilda. Universidad Complutense de Madrid; España
description To determine the dosage of enrofloxacin in southern crested caracaras (Caracara plancus), plasma concentrations of enrofloxacin were measured by high-performance liquid chromatography after intravenous (IV) (5 mg/kg) and intramuscular (IM) (10 mg/kg) administration. This compound presented a relatively high volume of distribution (2.09 L/kg), a total body clearance of 0.24 L/kg·h, and a long permanence as shown by an elimination half-life of 7.81 hours after IV administration and a terminal half-life of 6.58 hours after IM administration. The areas under the concentration-time curves (AUC) were 21.92 and 34.38 μg·h/mL for IM and IV administration, respectively. Enrofloxacin was rapidly absorbed after IM administration with a time to reach maximum concentration of 0.72 hours and bioavailability of 78.76%. After IM administration, the peak drug concentration (Cmax) was 3.92 μg/mL. Values of minimum inhibitory concentration (MIC), Cmax, and AUC have been used to predict the clinical efficacy of a drug in treating bacterial infections, with a Cmax/MIC value of 10 and an AUC/MIC ratio of 125-250 associated with optimal bactericidal effects. By using the study data and a MIC breakpoint of 0.25 μg/mL, values of Cmax/MIC were 13.74 and 15.94 and for AUC/MIC were 90.73 and 139.63, for the IV and IM routes respectively. For the treatment of infectious diseases caused by microorganisms with MIC ≤0.25 μg/mL, the calculated optimal dosages were 7.5 and 9.5 mg/kg q24h by the IV and IM routes, respectively. For less susceptible bacteria, a dose increase should be evaluated. To treat caracara by the IV route against microorganisms with MIC ≤0.25 μg/mL, the dose should be higher than the 5 mg/kg used in our study, but possible side effects derived from an increase in the IV dose and efficacy in sick birds should be assessed.
publishDate 2013
dc.date.none.fl_str_mv 2013-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/86056
Waxman Dova, Samanta; Prados, Ana Paula; De Lucas, Julio; Andres, Manuel Ignacio San; Sassaroli, Juan Carlos; et al.; Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus); Assoc Avian Veterinarians; Journal Of Avian Medicine And Surgery; 27; 3; 9-2013; 180-186
1082-6742
CONICET Digital
CONICET
url http://hdl.handle.net/11336/86056
identifier_str_mv Waxman Dova, Samanta; Prados, Ana Paula; De Lucas, Julio; Andres, Manuel Ignacio San; Sassaroli, Juan Carlos; et al.; Pharmacokinetic and pharmacodynamic properties of enrofloxacin in Southern crested caracaras (Caracara plancus); Assoc Avian Veterinarians; Journal Of Avian Medicine And Surgery; 27; 3; 9-2013; 180-186
1082-6742
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.bioone.org/doi/full/10.1647/2012-022
info:eu-repo/semantics/altIdentifier/doi/10.1647/2012-022
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Assoc Avian Veterinarians
publisher.none.fl_str_mv Assoc Avian Veterinarians
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269896367407104
score 13.13397

Publicaciones similares